NHS England's HIV Breakthrough Exposes a Global Equity Crisis

This week, NHS England announced that hundreds of patients living with multidrug-resistant HIV will soon receive lenacapavir, a revolutionary treatment that has been hailed as life-saving for those who have exhausted other options. The decision, welcomed by HIV campaigners, marks a significant step forward for the UK. Yet, as this innovation rolls out in England, the very communities abroad that helped make it possible remain locked out of access. This disparity raises uncomfortable questions about the ethics of medical progress in a globalised world.

Why is lenacapavir considered a breakthrough in HIV treatment?

Lenacapavir is not merely another antiretroviral. Administered as an injection just twice a year, it offers a paradigm shift in both HIV treatment and prevention. For individuals facing multidrug-resistant strains, it is a lifeline. For prevention, it removes the daily burden of pill-taking, a significant barrier for many who contend with stigma, criminalisation, financial insecurity, or geographic isolation. The potential to prevent new infections at scale is unprecedented, offering a tangible path toward ending AIDS as a public health threat by 2030.

What is the global cost disparity for lenacapavir?

The economics of lenacapavir are starkly inequitable. In wealthy nations, the drug commands a price of $28,000 to $40,000 (£21,000 to £29,000) per person annually. While some low-income countries are poised to access generic versions for as little as $40 (£29) per year, middle-income nations, including Brazil, Mexico, and Peru, are not so fortunate. These countries, which hosted the clinical trials essential to the drug's development, face the full commercial price, making access prohibitive. The bitter irony is that the communities instrumental in proving the drug's efficacy are now unable to benefit from it.

The HIV movement has long fought against the principle that geography or income should determine access to lifesaving care. To accept a future where wealthy nations enjoy the latest innovations while high-burden countries wait indefinitely would betray decades of advocacy and solidarity.

What are Médecins Sans Frontières' demands for equitable access?

Médecins Sans Frontières (MSF) has articulated three straightforward demands under its campaign, Lenacapavir: Two Shots. $40. Everywhere. First, the price of lenacapavir must fall below $40 per person per year in all low- and middle-income countries. Second, global supply must be increased to meet actual demand. Third, organisations working directly with communities, including MSF, must be permitted to purchase the drug directly. These are not radical propositions; they are the minimum requirements for ensuring this breakthrough reaches all who could benefit.

What role should the UK play in global HIV equity?

The UK now benefits from the scientific progress that produced lenacapavir. With this advantage comes a responsibility to leverage its financial and diplomatic influence for broader access. The UK should bolster organisations like Unitaid, which has already secured the $40-a-year price for generics, and the Global Fund, which supports country-level introduction and delivery. Furthermore, the UK must use its diplomatic leverage with Gilead, the manufacturer, to insist on licensing arrangements that prioritise people and communities over profit. The goal must be affordability and availability in every country where the drug is needed, not merely in the most lucrative markets.

Can the UK balance aid cuts with its global health ambitions?

There is a genuine opportunity for the UK to build on its historical leadership in global HIV response. However, this leadership is undermined by current cuts to aid spending and reductions in resources for global health. It is incoherent to profess a commitment to ending AIDS while diminishing support for the very partners, such as Unitaid and the Global Fund, that make progress possible. With just four years remaining to the 2030 target, the UK's new leadership faces a defining choice. If it is serious about ending AIDS as a public health threat, it must match its rhetoric with robust political and financial investment in equitable access.

Without such commitment, lenacapavir risks becoming another medical marvel reserved for the affluent, a symbol of innovation divorced from justice. The UK has the chance to champion a different narrative, one where scientific progress is harnessed for the common good. The question is whether it will seize that opportunity or allow a preventable tragedy to unfold.

Molly Thompson is senior advocacy advisor at STOPAIDS, an HIV, health and human rights advocacy network of 50 UK international development agencies. This article was produced as part of The Independent's Rethinking Global Aid project.